Liver toxicity of antiretroviral drugs

Seminars in Liver Disease

Volumn 32, Issue 2, 2012, Pages 167-176

  Jones, Michelle ^a   Núñez, Marina ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

antiretroviral therapy; DILI; drug induced liver injury; hepatotoxicity; HIV

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR PLUS RITONAVIR; CYTOCHROME P450 2B6; DARUNAVIR PLUS RITONAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR PLUS RITONAVIR; HLA B ANTIGEN; HLA DRB1 ANTIGEN; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL FEATURE; CONFERENCE PAPER; HEPATITIS; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LACTIC ACIDOSIS; LIVER CELL DAMAGE; LIVER FIBROSIS; LIVER TOXICITY; MIXED INFECTION; NONALCOHOLIC FATTY LIVER; PORTAL HYPERTENSION; PRIORITY JOURNAL; RISK FACTOR; TOXIC HEPATITIS;

ACIDOSIS, LACTIC; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG HYPERSENSITIVITY; DRUG-INDUCED LIVER INJURY; HIV; HIV INFECTIONS; HUMANS; LIVER;

EID: 84863213276     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0032-1316472     Document Type: Conference Paper

References (135)

1. Aithal GP, Watkins PB, Andrade RJ., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther: 2011; 89 6 806 815
2. Fontana RJ, Seeff LB, Andrade RJ., et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology: 2010; 52 2 730 742
3. Rockey DC, Seeff LB, Rochon J., et al. US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology: 2010; 51 6 2117 2126
4. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology: 1997; 26 3 664 669
5. Naranjo CA, Busto U, Sellers EM., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther: 1981; 30 2 239 245
6. Amacher DE. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol Appl Pharmacol: 2010; 245 1 134 142
7. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol: 1990; 11 2 272 276
8. Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. Hepatology: 2011; 53 4 1377 1387
9. Danan G, Benichou C. Causality assessment of adverse reactions to drugsI. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol: 1993; 46 11 1323 1330
10. AIDS Clinical Trials Group Table of Grading Severity of Adult Adverse Experiences. Rockville, MD Division of AIDS, National Institute of Allergy and Infectious Diseases: 1996
11. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA: 2000; 283 1 74 80
12. Guidance for industry drug-induced liver injury: premarketing clinical evaluation July 2009. Available at: http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed November 15, 2011
13. M'Kada H, Munteanu M, Perazzo H., et al. DILI group of the SAFE-T consortium. What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI). Regul Toxicol Pharmacol: 2011; 60 3 290 295
14. Núñez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology: 2010; 52 3 1143 1155
15. Lamivudine full prescribing information. Research Triangle Park, NC GlaxoSmithKline. Available at: http://www.epivir.com. Accessed October 17, 2011
16. Tenofovir full prescribing information. Foster City, CA Gilead Sciences, Inc. Available at: http://www.viread.com. Accessed October 17, 2011
17. Zidovudine full prescribing information. Research Triangle Park, NC GlaxoSmithKline. Available at: http://www.retrovir.com. Accessed October 17, 2011
18. Emtricitabine full prescribing information. Foster City, CA Gilead Sciences, Inc. Available at: http://www.emtriva.com. Accessed October 17, 2011
19. Abacavir full prescribing information. Research Triangle Park, NC GlaxoSmithKline. Available at: http://www.ziagen.com. Accessed October 17, 2011
20. Didanosine full prescribing information. Princeton, NJ Bristol-Myers Squibb. Available at: http://www.videx.com. Accessed October 17, 2011
21. Stavudine full prescribing information. Princeton, NJ Bristol-Myers Squibb. Available at: http://www.zerit.com. Accessed October 17, 2011
22. Rilpivirine full prescribing information. Raritan, NJ Tibotec, INc. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 202022s000lbl.pdf. Accessed October 17, 2011
23. Etravirine full prescribing information. Rarritan, NJ Tibotec Therapeutics. Available at: http://www.intelence.com. Accessed October 17, 2011
24. Delavirdine full prescribing information. New York, NY Pfizer, Inc. Available at: http://www.rescriptor.com. Accessed January 7, 2010
25. Efavirenz full prescribing information. Princeton, NJ Bristol-Myers Squibb. Available at: http://www.sustiva.com. Accessed October 17, 2011
26. Nevirapine full prescribing information. Ridgefield, CT Boehringer Ingelheim Pharmaceuticals, Inc. Available at: http://www.viramune.com. Accessed October 17, 2011
27. Nelfinavir full prescribing information. La Jolla, CA Agouron Pharmaceuticals, Inc. Available at: http://www.viracept.com. Accessed October 17, 2011
28. Indinavir full prescribing information. Whitehouse Station, NJ MERCK & CO. Available at: http://www.crixivan.com. Accessed October 17, 2011
29. Darunavir full prescribing information. Raritan, NJ Tibotec Therapeutics. Available at: http://www.prezista.com. Accessed October 17, 2011
30. Fosamprenavir full prescribing information. Research Triangle Park, NC GlaxoSmithKline. Available at: http://www.lexiva.com. Accessed October 17, 2011
31. Ritonavir full prescribing information. North Chicago, IL Abbott Laboratories. Available at: http://www.norvir.com. Accessed October 17, 2011
32. Atazanavir full prescribing information. Princeton, NJ Bristol-Myers Squibb. Available at: http://www.reyataz.com. Accessed October 17, 2011
33. Tipranavir full prescribing information. Ridgefield, CT Boehringer Ingelheim Pharmaceuticals, Inc. Available at: http://www.aptivus.com. Accessed October 17, 2011
34. Lopinavir full prescribing information. North Chicago, IL Abbott Laboratories. Available at: http://www.kaletra.com. Accessed October 17, 2011
35. Maraviroc full prescribing information. New York Pfizer Labs. Available at: http://www.selzentry.com. Accessed October 17, 2011
36. Raltegravir full prescribing information. Whitehouse Station, NJ MERCK & CO. Available at: http://www.isentress.com. Accessed October 17, 2011
37. Enfuvirtide full prescribing information. Durham, NC Trimeris, Inc. Available at: http://www.fuzeon.com. Accessed October 17, 2011
38. Saquinavir full prescribing information. Nutley, NJ Roche Laboratories Inc. Available at: http://www.invirase.com. Accessed October 17, 2011
39. den Brinker M, Wit FW, Wertheim-van Dillen PM., et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS: 2000; 14 18 2895 2902
40. Heil EL, Townsend ML, Shipp K, Clarke A, Johnson MD. Incidence of severe hepatotoxicity related to antiretroviral therapy in HIV/HCV coinfected patients. Aids Res Treat: 2010; 2010 856542
41. Chihrin S, Antoniou T, Raboud J., et al. Risk factors for grade 3-4 liver enzyme elevation in HIV and hepatitis C coinfected patients on combination antiretroviral therapy. AIDS Patient Care STDS: 2007; 21 7 469 478
42. Servoss JC, Kitch DW, Andersen JW, Reisler RB, Chung RT, Robbins GK. Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). J Acquir Immune Defic Syndr: 2006; 43 3 320 323
43. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis: 2002; 186 1 23 31
44. Lamar ZS, Núnez M. Higher risk of severe drug-induced liver injury among Hispanic HIV-infected patients after initiation of highly active antiretroviral therapy. J Int Assoc Physicians AIDS Care (Chic): 2011; 10 3 183 186 (JIAPAC)
45. Kovari H, Ledergerber B, Battegay M., et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus co-infection. Clin Infect Dis: 2010; 50 4 502 511
46. Shores NJ, Maida I, Perez-Saleme L, Núñez M. Virological rather than host factors are associated with transaminase levels among HIV/HCV-coinfected patients. J Int Assoc Physicians AIDS Care (Chic): 2010; 9 1 15 19
47. Crum-Cianflone N, Dilay A, Collins G., et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr: 2009; 50 5 464 473
48. Marks KM, Petrovic LM, Talal AH, Murray MP, Gulick RM, Glesby MJ. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis: 2005; 192 11 1943 1949
49. Tedaldi EM, Absalon J, Thomas AJ, Shlay JC, van den Berg-Wolf M. Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr: 2008; 47 4 441 448
50. Currier J, Spino C, Grimes J., et al. Differences between women and med in adverse events and CD4 responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr: 2000; 24 316 324
51. Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med: 2003; 11 2 55 59
52. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr: 2003; 34 Suppl 1 S21 S33
53. Sanne I, Mommeja-Marin H, Hinkle J., et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis: 2005; 191 6 825 829
54. Kesselring AM, Wit FW, Sabin CA., et al. Nevirapine Toxicity Multicohort Collaboration. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS: 2009; 23 13 1689 1699
55. Wit FW, Kesselring AM, Gras L., et al. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study. Clin Infect Dis: 2008; 46 6 933 940
56. Martin AM, Nolan D, James I., et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1 0101 and abrogated by low CD4 T-cell counts. AIDS: 2005; 19 1 97 99
57. Martin AM, Nolan D, Gaudieri S., et al. Predisposition to abacavir hypersensitivity conferred by HLA-B 5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A: 2004; 101 12 4180 4185
58. Wyen C, Hendra H, Vogel M., et al. German Competence Network for HIV/AIDS. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother: 2008; 61 4 914 918
59. Leger P, Dillingham R, Beauharnais CA., et al. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. J Infect Dis: 2009; 200 6 955 964
60. Yimer G, Amogne W, Habtewold A., et al. High plasma efavirenz level and CYP2B66 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J: 2011;; Aug 23. doi: 10.1038/tpj.2011.34. [Epub ahead of print]
61. Mallal S, Phillips E, Carosi G., et al. PREDICT-1 Study Team. HLA-B5701 screening for hypersensitivity to abacavir. N Engl J Med: 2008; 358 6 568 579
62. Saag M, Balu R, Phillips E., et al. Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. High sensitivity of human leukocyte antigen-b5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis: 2008; 46 7 1111 1118
63. Johnson S, Chan J, Bennett C. Hepatotoxicity after prophylaxis with a nevirapine containing antiretroviral regimen. Ann Intern Med: 2002; 137 2 146 147
64. Centers for Disease Control and Prevention (CDC) Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposuresworldwide, 1997-2000. MMWR Morb Mortal Wkly Rep: 2001; 49 51-52 1153 1156
65. Pavel S, Burty C, Alcaraz I., et al. Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen. AIDS: 2007; 21 2 268 269
66. Anonymous Liver toxicity warning for darunavir. AIDS Patient Care STDS: 2008; 22 4 346
67. Claudio GA, Martin AF, de Dios Perrino S, Velasco AA. DRESS syndrome associated with nevirapine therapy. Arch Intern Med: 2001; 161 20 2501 2502
68. Leung JM, O'Brien JG, Wong HK, Winslow DL. Efavirenz-induced hypersensitivity reaction manifesting in rash and hepatitis in a Latino male. Ann Pharmacother: 2008; 42 3 425 429
69. Turkova A, Ball C, Gilmour-White S, Rela M, Mieli-Vergani G. A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation. J Antimicrob Chemother: 2009; 63 3 623 625
70. Montaner JS, Reiss P, Cooper D., et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA: 1998; 279 12 930 937
71. Carr A, Vella S, de Jong MD., et al. The Dutch-Italian-Australian Nevirapine Study Group A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. AIDS: 1996; 10 6 635 641
72. D'Aquila R, Hughes M, Johnsons V., et al. Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med: 1996; 124 1019 1030
73. Hernandez J, Cutrell A, Edwards M, Fleming J, Powell W, Scott T. Clinical risk factors for hypersensitivity reactions to abacavir: retrospective analysis of over 8,000 subjects receiving abacavir in 34 clinical trials. Paper presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL
74. Hetherington S, McGuirk S, Powell G., et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther: 2001; 23 10 1603 1614
75. Lactic Acidosis International Study Group Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS: 2007; 21 18 2455 2464
76. Arenas-Pinto A, Grant AD, Edwards S, Weller IV. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect: 2003; 79 4 340 343
77. Batisse D, Duong Van Huyen JP, Piketty C., et al. Severe liver mitochondriopathy with normal liver histology and normal lactate levels in patients receiving nucleoside analogues. AIDS: 2002; 16 17 2370 2371
78. Calza L, Manfredi R, Chiodo F. Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. Clin Nutr: 2005; 24 1 5 15
79. Apostolova N, Blas-García A, Esplugues JV. Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-γ inhibition. Trends Pharmacol Sci: 2011; 32 12 715 725
80. Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol: 1999; 15 6 367 373
81. Montessori V, Harris M, Montaner JS. Hepatotoxicity of nucleoside reverse transcriptase inhibitors. Semin Liver Dis: 2003; 23 2 167 172
82. Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: mechanisms and test systems. Hepatology: 2001; 33 4 1009 1013
83. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS: 2002; 16 10 1341 1349
84. U.S. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for use of antiretroviral agents in HIV-1 infected adults and adolescents. January 10, 2011. Available at: http://www.aidsinfo.nih.gov/Guidelines/GuidelineHTML.aspx?GuidelineID= 7&docID=1&NodeID=12. Accessed October 11, 2011
85. Brinkman K, ter Hoftede HJM. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: lactic acidosis, risk factors and therapeutic options. AIDS Rev: 1999; 1 141 148
86. ter Hofstede HJ, de Marie S, Foudraine NA, Danner SA, Brinkman K. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS: 2000; 11 9 611 616
87. Sulkowski MS, Mehta SH, Torbenson M., et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS: 2005; 19 6 585 592
88. Rodríguez-Torres M, Govindarajan S, Solá R., et al. Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study. J Hepatol: 2008; 48 5 756 764
89. Guaraldi G, Squillace N, Stentarelli C., et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis: 2008; 47 2 250 257
90. Woreta T, Sutcliffe C, Mehta S., et al. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology: 2011; 140 809 817
91. Szabo G, Zakhair S. Mechanisms of alcohol-related hepatotoxicity in human-immunodeficiency-virus-infected patients. World J Gastroenterol: 2011; 17 2500 2506
92. Bani-Sadr F, Carrat F, Bedossa P., et al. ANRS HC02 - Ribavic Study team. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS: 2006; 20 4 525 531
93. Neau D, Winnock M, Castéra L., et al. Groupe d'Epidé miologie Clinique du SIDA en Aquitaine. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort. J Acquir Immune Defic Syndr: 2007; 45 2 168 173
94. Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology: 2011; 54 3 1071 1081
95. Maida I, Núñez M, Ríos MJ., et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr: 2006; 42 2 177 182
96. Arey B, Markov M, Ravi J, Prevette E, Batts K, Nadir A. Nodular regenerative hyperplasia of liver as a consequence of ART. AIDS: 2007; 21 8 1066 1068
97. Chang PE, Miquel R, Blanco JL., et al. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol: 2009; 104 7 1707 1714
98. Diaz HA, Callejo AM, Martinez A, Rodriguez JFG. Non-cirrhotic portal hypertension in HIV-infected patients: A new challenge in antiretroviral therapy. AIDS: 2011; 5 59 61
99. Schiano TD, Kotler DP, Ferran E, Fiel MI. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol: 2007; 102 11 2536 2540
100. Chang PE, Garcia-Pagan JC. Idiopathic noncirrhotic portal hypertension in HIV-infected patients. Clin Infect Dis: 2010; 50 1 127 128, author reply 128-129
101. Schiano TD, Uriel A, Dieterich DT, Fiel MI. The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV. Virchows Arch: 2011; 458 2 231 235
102. Garvey LJ, Thomson EC, Lloyd J, Cooke GS, Goldin RD, Main J. Response to Mallet et al., 'Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients'. AIDS: 2007; 21 11 1494 1495
103. Sandrine PF, Sylvie A, André E, Abdoulaye D, Bernard L, André C. Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect? AIDS: 2007; 21 11 1498 1499
104. Saifee S, Joelson D, Braude J., et al. Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection. Clin Gastroenterol Hepatol: 2008; 6 1167 1169
105. Mallet V, Blanchard P, Verkarre V., et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS: 2007; 21 2 187 192
106. Kovari H, Ledergerber B, Peter U., et al. Swiss HIV Cohort Study. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis: 2009; 49 4 626 635
107. Scourfield A, Waters L, Holmes P., et al. Non-cirrhotic portal hypertension in HIV-infected individuals. Int J STD AIDS: 2011; 22 6 324 328
108. Vispo E, Moreno A, Maida I., et al. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS: 2010; 24 8 1171 1176
109. Vispo E, Morello J, Rodriguez-Novoa S, Soriano V. Noncirrhotic portal hypertension in HIV infection. Curr Opin Infect Dis: 2011; 24 1 12 18
110. Carr A, Morey A, Mallon P, Williams D, Thorburn DR. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet: 2001; 357 9266 1412 1414
111. Maida I, Garcia-Gasco P, Sotgiu G., et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther: 2008; 13 1 103 107
112. Hillaire S, Bonte E, Denninger MH., et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut: 2002; 51 2 275 280
113. Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis: 2003; 23 2 183 194
114. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS: 2004; 18 17 2277 2284
115. Gathe JC Jr, Pierone G, Piliero P., et al. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients. AIDS Res Hum Retroviruses: 2007; 23 2 216 223
116. van Leth F, Phanuphak P, Ruxrungtham K., et al. 2NN Study team Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet: 2004; 363 9417 1253 1263
117. González de Requena D, Núñez M, Jiménez- Nácher I, Soriano V. Liver toxicity caused by nevirapine. AIDS: 2002; 16 2 290 291
118. Núñez M, González-Requena D, González-Lahoz J, Soriano V. Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients. AIDS Res Hum Retroviruses: 2003; 19 3 187 188
119. Kappelhoff BS, van Leth F, Robinson PA., et al. 2NN Study Group Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther: 2005; 10 4 489 498
120. Núñez M, Ríos P, Martín-Carbonero L, Pérez-Olmeda M, González-Lahoz J, Soriano V. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr: 2002; 30 1 65 68
121. Maida I, Babudieri S, Selva C., et al. Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: role of HCV genotypes. AIDS Res Hum Retroviruses: 2006; 22 2 139 143
122. Torti C, Lapadula G, Puoti M., et al. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. J Acquir Immune Defic Syndr: 2006; 41 2 180 185
123. Yunihastuti E, Lee S, Gani R., et al. Antibody and markers of T-cell activation illuminate the pathogenesis of HCV immune restoration disease in HIV/HCV co-infected patients commending ART. Clin Immunol: 2011; 139 1 32 39
124. John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS: 1998; 12 17 2289 2293
125. Ofotokun I, Smithson SE, Lu C, Easley KA, Lennox JL. Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy. Am J Med Sci: 2007; 334 5 334 341
126. Stone SF, Lee S, Keane NM, Price P, French MA. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients. J Infect Dis: 2002; 186 10 1498 1502
127. Crane M, Oliver B, Matthews G., et al. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis: 2009; 199 7 974 981
128. Macías J, Castellano V, Merchante N., et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS: 2004; 18 5 767 774
129. Fuster D, Planas R, Muga R., et al. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. AIDS Res Hum Retroviruses: 2004; 20 12 1293 1297
130. Sterling RK, Wilson MS, Sanyal AJ., et al. Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection. Clin Gastroenterol Hepatol: 2004; 2 5 432 439
131. Berenguer J, Bellón JM, Miralles P., et al. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis: 2008; 46 1 137 143
132. Jones M, Núñez M. HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management. Curr Opin HIV AIDS: 2011; 6 6 546 552
133. McLean AJ, Cogger VC, Chong GC., et al. Age-related pseudocapillarization of the human liver. J Pathol: 2003; 200 1 112 117
134. Labarga P, Soriano V, Vispo ME., et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis: 2007; 196 5 670 676
135. Vispo E, Mena A, Maida I., et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother: 2010; 65 3 543 547